0RD1 Stock Overview
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Camurus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr478.07 |
| 52 Week High | kr596.00 |
| 52 Week Low | kr221.40 |
| Beta | 0.84 |
| 1 Month Change | -5.48% |
| 3 Month Change | -5.33% |
| 1 Year Change | 113.40% |
| 3 Year Change | 127.65% |
| 5 Year Change | 548.67% |
| Change since IPO | 625.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RD1 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -1.0% | -1.3% | -0.9% |
| 1Y | 113.4% | -5.5% | -1.8% |
Return vs Industry: 0RD1 exceeded the UK Pharmaceuticals industry which returned -5.5% over the past year.
Return vs Market: 0RD1 exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0RD1 volatility | |
|---|---|
| 0RD1 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RD1 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0RD1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 213 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.
Camurus AB (publ) Fundamentals Summary
| 0RD1 fundamental statistics | |
|---|---|
| Market cap | kr27.37b |
| Earnings (TTM) | kr431.44m |
| Revenue (TTM) | kr1.72b |
63.4x
P/E Ratio15.9x
P/S RatioIs 0RD1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RD1 income statement (TTM) | |
|---|---|
| Revenue | kr1.72b |
| Cost of Revenue | kr122.35m |
| Gross Profit | kr1.59b |
| Other Expenses | kr1.16b |
| Earnings | kr431.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 7.49 |
| Gross Margin | 92.87% |
| Net Profit Margin | 25.13% |
| Debt/Equity Ratio | 0% |
How did 0RD1 perform over the long term?
See historical performance and comparison